CORE FOCUS
HOME / CORE FOCUS
Gastrointestinal
An increasing range of disease conditions from inflammatory bowel disease to non-alcoholic steatohepatitis and colorectal cancer are associated with gut pathobionts.
​​
Our expertise in clinical gastroenterology includes direct experience of patient needs that drive demand for therapeutic innovation.
​​
We are well-versed in the language of microbiology and molecular biochemistry that underpins disease and therapeutic discovery processes.
​​
Our experience in clinical trial conduct affords additional nuanced insights into practical challenges an investigational intervention may face.
Microbial Diseases
The age of whole genome sequencing has ushered novel insights into potential virulence pathways in even previously known pathogens.
​​
Still under-appreciated is the role of secondary metabolites and microbial-microbial interactions that promote disease in the host.
​​
Practice is already moving beyond whole-microbiome approaches like fecal transplantation and will move further beyond whole microbe approaches to molecular biochemistry underpinnings of therapy.
​​
Translating knowledge we gain from concept to therapy and then market will require risk-reward profiling that appreciates the science and medicine of product development and is forward looking to maximize impact opportunities.
